Is fosfomycin effective for coverage of Pseudomonas aeruginosa?

Fosfomycin Has Limited and Unreliable Activity Against Pseudomonas aeruginosa

Fosfomycin should NOT be used as monotherapy for Pseudomonas aeruginosa infections due to poor intrinsic activity, rapid resistance development, and lack of established clinical breakpoints. If used at all, it must be combined with another active antipseudomonal agent in severe infections where the isolate is confirmed susceptible.

Critical Limitations from FDA Drug Label

The FDA-approved fosfomycin label 1 does not list Pseudomonas aeruginosa among organisms with established clinical efficacy. The label explicitly states that organisms like Serratia marcescens and various Enterobacteriaceae have in vitro MICs ≤64 mcg/mL, but "the safety and effectiveness of fosfomycin in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials." Notably absent from even this list is P. aeruginosa.

Why Fosfomycin Fails Against Pseudomonas

Intrinsic Resistance Mechanisms

• P. aeruginosa has fundamentally different resistance mechanisms than Enterobacteriaceae, including chromosomal Fos enzymes, peptidoglycan recycling enzymes, and transporter mutations 2
• These mechanisms result in elevated MICs that cannot be predicted using E. coli breakpoints 2
• Baseline heteroresistance is present in all tested isolates, with rapid replacement by resistant colonies during treatment 3

Poor Pharmacodynamics

• Time-kill studies demonstrate only moderate killing (~3 log reduction) with complete regrowth by 24 hours 3
• Bacterial killing is virtually eliminated at high inoculum (10^8 CFU/mL), which is clinically relevant in pneumonia 3
• Monotherapy results in rapid emergence of resistance even at concentrations up to 1024 mg/L 3

Variable and Poor Susceptibility

• Only 30.2% (511/1693) of MDR P. aeruginosa isolates were susceptible to fosfomycin across multiple studies 4
• Recent data from cystic fibrosis patients showed 77.2% resistance to fosfomycin 5
• MIC50 and MIC90 values of 32 and 64 mcg/mL respectively suggest marginal activity at best 6

When Fosfomycin Might Be Considered (With Major Caveats)

Combination Therapy Only

The 2022 ESCMID guidelines 7 suggest using two in vitro active drugs for severe carbapenem-resistant P. aeruginosa (CRPA) infections when polymyxins, aminoglycosides, or fosfomycin are options. However, this is a conditional recommendation based on very low-quality evidence.

Key requirements if considering fosfomycin combinations:

• Confirm susceptibility through antimicrobial susceptibility testing before use 8
• Never use as monotherapy - resistance emerges within 24 hours 3
• Best synergy rates observed with:
  • Ceftazidime (23.4% synergy rate) 9
  • Gentamicin (19.1% synergy rate) 9
  • Beta-lactams and colistin for biofilm inhibition 10

Limited Clinical Evidence

• One small study (48 ICU patients with CRPA/CRKP) using fosfomycin combinations showed 54.2% treatment efficacy and 37.5% 28-day mortality 8
• Most clinical data (33 patients) comes from cystic fibrosis pulmonary exacerbations, not systemic infections, with 91% clinical improvement when combined with other antibiotics 4
• No comparative trials demonstrate superiority over standard antipseudomonal regimens

Practical Algorithm

For suspected or confirmed P. aeruginosa infection:

1. First-line options: Use proven antipseudomonal agents (ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relebactam, cefiderocol, or polymyxin-based combinations) 7

2. If considering fosfomycin (salvage therapy only):

   • Obtain susceptibility testing with synergy testing
   • Use only if MIC ≤32 mcg/mL AND synergy demonstrated
   • Always combine with another active agent (preferably ceftazidime or aminoglycoside)
   • Avoid in patients with hypernatremia, cardiac or renal insufficiency 8

3. For pneumonia specifically: Even higher doses (8g q8h) may be needed to achieve adequate epithelial lining fluid concentrations 11, making this impractical

Common Pitfalls to Avoid

• Do not extrapolate E. coli UTI data to P. aeruginosa systemic infections - completely different resistance mechanisms 2
• Do not use fosfomycin monotherapy - resistance is inevitable 3
• Do not assume in vitro synergy translates to clinical efficacy - only 53.5% of isolates showed synergy even in favorable laboratory conditions 4
• Do not use without documented susceptibility - 70-77% of isolates may be resistant 4, 5

Bottom line: Fosfomycin has no established role for P. aeruginosa infections outside of highly selected cases with documented susceptibility used in combination therapy when no other options exist.